Jiaogulan for Health & Longevity - Quick Reference Sheet

Jiaogulan for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Jiaogulan is an East Asian climbing plant used as an oral tea or supplement extract for blood sugar control, fat loss, and endurance. In short-term human trials, leaf tea lowers elevated blood sugar and insulin resistance, while heat-processed extract modestly reduces abdominal and hip fat and improves endurance. Cholesterol and liver enzyme benefits occur mainly as an add-on, and rare reversible blood cell drops warrant monitoring. (Full Review)

Protocol

Standard AMPK and body-composition extract regimen
450 mg/day oral extract
Heat-processed extract standardized to damulins A (≥1.1–2.49%) and B (≥1.06%), administered orally as 225 mg twice daily or 450 mg once daily
Traditional glycemic leaf-tea regimen
6 g/day whole-leaf tea
Authenticated dried whole leaves (~18% gypenosides) infused in warm water and administered orally as 3 g twice daily
Optimal time of day
30 min pre-meal or 60 min pre-exercise
30 minutes before breakfast and dinner for glycemic and body-composition goals, or 60 minutes before endurance training
Time to effect
Glycemic control and insulin sensitivity
Within 4 weeks
Fasting glucose and insulin sensitivity improvements within 4 weeks with 6 g/day leaf tea; HbA1c reductions over 8–12 weeks
Body weight and visceral fat reduction
12–16 weeks
Total abdominal, visceral (males), and gynoid (females) fat mass reductions with 450 mg/day heat-processed extract
Endurance exercise performance and fatigue resistance
4–12 weeks
Muscle AMPK phosphorylation and 20-km cycling performance within 4 weeks; VO₂ max and fatigue resistance over 12 weeks

Benefits

Contraindications
  • Individuals with baseline thrombocytopenia (platelet count <150 × 109/L) or history of drug-induced cytopenia
  • Pregnant or breastfeeding women
  • Surgical patients within 14 days prior to scheduled invasive procedures
  • Patients with decompensated cardiovascular disease (arrhythmia, heart failure, myocardial infarction, or pacemaker), acute or chronic renal failure, abnormal hepatic function, or prior gastrointestinal surgery
  • Individuals with active autoimmune disorders or organ transplants receiving immunosuppressive therapy (cyclosporine, tacrolimus, azathioprine, mycophenolate, prednisone)
Key Interactions
  • Sulfonylureas (insulin-releasing diabetes drugs) and antidiabetics (gliclazide, glimepiride, metformin, insulin)
  • CYP2D6-metabolized medications (metoprolol, carvedilol, fluoxetine, paroxetine, tamoxifen)
  • CYP2C8, CYP3A4, CYP2C9, and UGT1A4 substrates (atorvastatin, midazolam, losartan, warfarin, lamotrigine)
  • Anticoagulant and antiplatelet prescription medications (warfarin, apixaban, rivaroxaban, clopidogrel)
  • Over-the-counter nonsteroidal anti-inflammatory drugs and salicylates (aspirin, ibuprofen, naproxen)
  • AMPK-activating and hypoglycemic supplements (berberine, alpha-lipoic acid, Gymnema sylvestre, chromium)
  • Antiplatelet and fibrinolytic supplements (Ginkgo biloba, nattokinase, omega-3 fatty acids, garlic extract)
  • Prolonged multi-day fasting protocols

Risk & Side Effects

  • High:
  • Medium:
  • Low: Thrombocytopenia, leukopenia, and mild hematological shifts; mild gastrointestinal discomfort; genotype-specific HDL cholesterol reduction
  • Speculative: Platelet aggregation inhibition and bleeding tendency; additive hypoglycemia with antidiabetic medications; immune stimulation in autoimmune conditions

Monitoring

Marker Target Why
Fasting Plasma Glucose 3.9–5.5 mmol/L (70–99 mg/dL) Efficacy marker (expected to decrease in insulin resistance) and safety check for hypoglycemia
HbA1c <5.7% Efficacy marker (expected to decrease over 8–12 weeks in elevated states)
Serum Triglycerides <1.7 mmol/L (<150 mg/dL) Efficacy marker (expected to decrease via AMPK and FXR hepatic lipid oxidation)
Serum HDL-C >1.0 mmol/L men, >1.3 mmol/L women Efficacy marker (generally increases) and safety check in CETP B2 / non-APOE4 carriers (discontinuation threshold: >10% drop)
Platelet & Leukocyte Count (CBC) Platelets 150–450 × 109/L; WBC 4.5–11.0 × 109/L Safety check for thrombocytopenia or leukopenia (discontinuation threshold: platelets <150 × 109/L)
Liver Enzymes (ALT, AST, ALP) ALT 7–56 U/L; AST 8–33 U/L; ALP 44–147 U/L Efficacy marker in fatty liver disease and baseline safety check
Visceral & Total Fat Mass (DEXA) No established target; reduction from individual baseline Efficacy marker (expected to decrease over 12–16 weeks with damulin-standardized extract)

Cadence: Baseline (fasting glucose, fasting insulin/HOMA-IR, HbA1c, lipid panel including triglycerides/HDL-C/LDL-C, CBC with differential and platelets, ALT/AST/ALP, and optional DEXA scan), 4 weeks (fasting glucose, HDL-C, platelets), 12–16 weeks (HbA1c, triglycerides, liver enzymes, repeat DEXA), and every 6 months during continued use.

Qualitative Assessment

  • Endurance and perceived exertion: 20-km cycling splits and post-exercise fatigue over 4–12 weeks.
  • Stress resilience: Trait anxiety over 8 weeks.
  • Digestive and bruising tolerance: Absence of nausea or easy bruising.